Results 201 to 210 of about 74,867 (310)

ACTH bioassay with isolated rat adrenal cells: ACTH activity of the porcins lipotropic peptide B [PDF]

, 1974
Baur, X., Marschner, I., Müller, O. A., Schwandt, P., Scriba, Peter Christian, Weisweiler, P.   +5 more
core   +1 more source

Gαs defines the fundamental coupling mechanism of insulin secretion. [PDF]

J Diabetes Investig
Shirakawa J.
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Group Experiments on the Radioimmunological Insulin Determination [PDF]

, 1974
Bottermann, P., Erhardt, F., Linke, R., Löffler, G., Maier, V., Marschner, I., Schwandt, P., Scriba, Peter Christian, Vogt, W.   +8 more
core   +1 more source

The role of chromogranin A cleavage products in onset of type 1 and 2 diabetes. [PDF]

Front Clin Diabetes Healthc
Christoffersson G, Muntjewerff EM.
europepmc   +1 more source

G Protein‐Coupled Receptor 17 (Gpr17) Enhances Leptin and Insulin Sensitivity in Lean and Obese Mouse Models

Obesity, EarlyView.
This study identifies G protein‐coupled receptor 17 (Gpr17) as a novel regulator of leptin and insulin sensitivity. Using complementary knockout models, we demonstrate that Gpr17 deletion enhances energy expenditure, restores leptin responsiveness, and improves insulin sensitivity, revealing Gpr17 as a potential therapeutic GPCR target for obesity and ...
Xun Sun, Connor Mahler, Natalie D. Stull, Ali Nasiri, Baohua Zhou, Varman Samuel, Gerald Shulman, Jonathan N. Flak, Hongxia Ren   +8 more
wiley   +1 more source

Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity. [PDF]

RSC Med Chem
Kalinowska I, Gawalska A, Kasprzycka P, Stępniewski M, Rózga P, Pałka A, Shubin A, Bukato K, Gałązka M, Burchard E, Zielińska-Świder P, Jaworski A, Feder M.   +12 more
europepmc   +1 more source

Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs). Methods Commercial insurance claims were used to identify new initiators of phentermine (n = 136,788), phentermine‐topiramate‐ER (n = 13,888), naltrexone‐bupropion‐SR (n = 28,712), or liraglutide (n = 49,266) for obesity.
Kristina H. Lewis, Fang Zhang, Robert F. LeCates, Stephanie Argetsinger, Stefanie Albert, Geetha S. Iyer, John G. Connolly, James F. Wharam, David E. Arterburn, Dennis Ross‐Degnan, Sengwee Toh   +10 more
wiley   +1 more source

Improving incretin-mediated body weight loss via energy expenditure. [PDF]

Trends Endocrinol Metab
Elmendorf AJ, Douros JD, Knerr PJ, Flak JN.   +3 more
europepmc   +1 more source

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

Obesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain, Mohanad Albayyaa, Rasmi Nair, Yong‐Fang Kuo, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah   +10 more
wiley   +1 more source